Contraceptive pills induce an improvement in congenital hypoplasminogenemia in two unrelated patients with ligneous conjunctivitis

Summary

Severe type I plasminogen deficiency is the underlying cause of ligneous conjunctivitis, a rare disease characterized by wood-like pseudomembranes developing on the ocular and extraocular mucosa. Two unrelated female patients with ligneous conjunctivitis and moderate hypoplasminogenemia are described. Being of fertile age, they were treated with oral contraceptives, which determined a marked increase in plasminogen levels. Moreover, a palpebral pseudomembrane stopped growing in one patient and disappeared completely in the other while on the estroprogestinic treatment. In patient n.2,who also suffered from von Willebrand’s disease, prior Cushing’s disease induced an increase in both von Willebrand factor and plasminogen levels, which dropped after curative hypophysectomy. Genetic plasminogen study showed a 19Lys>Glu mutation in a heterozygous state in the first proposita and in a homozygous state in the second proband. In addition, both index patients were homozygous for a new intron F-14T>G mutation, which was found to reduce the acceptor splicing site prediction score.

In conclusion, oral contraceptive therapy may improve plasminogen deficiency and deserves attention as an alternative therapeutic approach in selected cases of ligneous conjunctivitis with low, but not absent, plasminogen synthesis.

Keywords

Plasminogen deficiency - ligneous conjunctivitis - oral contraceptives - plasminogen gene mutations - von Willebrand’s disease

• References

• 1 Cohen SR. Ligneous conjunctivitis: an ophthalmic disease with potentially fatal tracheo-bronchial obstruction. Laryngeal and tracheo-bronchial features. Ann Otol Rhinol Laryngol 1990; 99: 509-12.
• 2 Scurry J. et al. Ligeous (pseudomembranous) inflammation of the female genital tract. A report of two cases. J Reprod Med 1993; 38: 407-12.
• 3 Parunovic A, Stefanovic D. Conjunctivitis lignosa and hydrocephalus (an unusual association of 2 diseases). Vestn Oftalmol 1993; 109: 30-1.
• 4 Mingers AM, Heimburger N, Lutz E. Familiärer homozygoter und heterozygoter Typ I-Plasmonigenmangel. In: Scharrer I, Schramm W (eds). 25 Hämophilie-Symposium 1994; Springer, Berlin: 1995: 96-104.
• 5 Mingers AM. et al. Human homozygous type I plasminogen deficiency and ligneous conjunctivitis. APMIS 1999; 107: 62-72.
• 6 Ramsby ML. et al. Ligneous conjunctivitis: biochemical evidence for hypofibrinolysis. Inflammation 2000; 24: 45-71.
• 7 Schuster V. et al. Homozygous mutations in the plasminogen gene of two unrelated girls with ligneous conjunctivitis. Blood 1997; 90: 958-66.
• 8 Schuster V. et al. Compound-heterozygous mutations in the plasminogen gene predispose to the development of ligneous conjunctivitis. Blood 1999; 93: 3457-66.
• 9 Schott D. et al. Therapy with a purified plasminogen concentrate in an infant with ligneous conjunctivitis and homozygous plasminogen deficiency. N Engl J Med 1998; 339: 1679-86.
• 10 Schuster V. et al. Homozygous and compound-heterozygous type I plasminogen deficiency is a common cause of ligneous conjunctivitis. Thromb Haemost 2001; 85: 1004-10.
• 11 Nussgens Z, Roggenkamper P. Ligneous conjunctivitis: ten years follow-up. Ophthalmic Pediatr Genet 1993; 14: 137-40.
• 12 Schwartz GS, Holland EJ. Induction of ligneous conjunctivitis by conjunctival surgery. Am J Ophthalmol 1995; 120: 253-4.
• 13 Watts P. et al. Effective treatment of ligneous conjunctivitis with topical plasminogen. Am J Ophthalmol 2002; 133: 451-5.
• 14 Wright JG. et al. Fibrinolysis during normal human pregnancy: complex inter-relationships between plasma levels of tissue plasminogen activator and inhibitors and the euglobulin clot lysis time. Br J Haematol 1988; 69: 253-8.
• 15 Patrassi GM. et al. Further studies on the hypercoagulable state of patients with Cushing’s sindrome.. Thromb Haemost 54 1985; 1985: 518-20.
• 16 Tait RC, Walzer I, Conie JA. et al. Plasmino-gen levels in healthy volunteers – Influence of age, sex, smoking and oral contraceptives. Thromb Haemost 1992; 68: 506-10.
• 17 Shigekiyo T, Tomonari A, Uno Y, Kishi Y. Danazol therapy in hypoplasminogenemia. Thromb Haemost 1992; 68: 233-4.
• 18 Mannucci PM. et al. Congenital plasminogen deficiency associated with venous thromboembolism: therapeutic trial with stanozolol. Br J Haematol 1986; 63: 753-9.
• 19 Soria C. et al. Dosage dù plasminogène à l’aide d’un substrate chromogène tripeptidique. Pathol Biol 1976; 24: 725-29.
• 20 Laurell CB. Quantitative estimation of proteins by electrophoresis of human serum proteins. Annal Biochem 1966; 15: 45-52.
• 21 Casonato A. et al. Impaired release of tissue plasminogen activator (t-PA) following DDAVP infusion in von Willebrand’s disease with low platelet and von Willebrand factor content. Blood Coagul Fibrinolysis 1992; 3: 149-53.
• 22 Casonato A. et al. The evaluation of factor VIII antigen by means of a simple slide test. Am J Clin Pathol 1985; 84: 107-11.
• 23 Girolami A. et al. A new congenital haemorrhagic condition due to the presence of abnormal factor X (factor X Friuli): study of a large kindred. Br J Haematol 1970; 19: 179-92.
• 24 Friederich PW. et al. Frequency of pregnancy-related venous thromboembolism in anticoagulant factor-deficient women: implication for prophylaxis. Ann Int Med 1996; 125: 955-60.
• 25 Simioni P. et al. Pseudohomozygous activated protein C resistance due to double heterozygous factor V defect (factor V Leiden mutation and type I quantitative factor V defect) associated with thrombosis: report of two cases belonging to two unrelated kindreds. Thromb Haemost 1996; 75: 422-26.
• 26 Eriksson E. et al. Determination of plasmino-gen activator inhibitor in plasma using t-PA and chromogenic single point poly-D-lysine stimulated assay. Thromb Res 1988; 50: 91-101.
• 27 Declerck PJ. et al. Measurement of plasmino-gen activator inhibitor 1 in biological fluids with a murine monoclonal antibody-based enzyme-linked immunoassay. Blood 1988; 71: 220-25.
• 28 Holvoet P. et al. Assay of human tissue plasminogen activator (t-PA) with an enzyme-linked immunosorbent assay (ELISA) based on three murine monoclonal antibodies to t-PA. Thromb Haemost 1985; 54: 684-87.
• 29 Azuma H. et al. Congenital plasminogen deficiency caused by a Ser572 to Pro mutation. Blood 1993; 82: 475-80.
• 30 Petersen TE. et al. Characterization of the gene for human plasminogen, the key proenzyme in the fibrinolytic system. J Biol Chem 1990; 265: 6104-11.
• 31 Sartori MT. et al. Familial association of hypo-plasminogenemia and heterozygous factor V deficiency. Clin Appl Thrombosis/Hemostasis 1999; 5: 277-81.
• 32 Sartori MT. et al. Combined heterozygous plasminogen deficiency and factor V Leiden defect in the same kindred. Clin Appl Thrombosis/Hemostasis 2000; 6: 36-40.
• 33 Manabe S. et al. Homozygous protein C deficiency combined with heterozygous dysplasminogenemia found in a 21-year-old thrombophilic male. Thromb Res 1985; 39: 333-41.
• 34 Mateo J. et al. Laboratory evaluation and clinical characteristics of 2132 consecutive unselected patients with venous thromboembolism – results of the Spanish Multicentric Study on Thrombophilia (EMET Study). Thromb Haemost 1997; 77: 444-51.